MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), penicillin-intermediate S. pneumoniae (PISP), and vancomycin-resistant enterococci (VRE). Orally administered MRX-I showed the same or better efficacy than linezolid in systemic and local infection mouse models.
MRX-1 is in Phase 3 clinical trial in China.
MRX4, a prodrug of MRX-1, is in Phase 1 trial in the U.S. MicruRX Press Release November 30,2016. https://clinicaltrials.gov/show/NCT03033329